Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AbbVie will pay up to $212 million to acquire Landos Biopharma, bolstering its ulcerative colitis pipeline with an experimental oral drug that targets a novel…
AbbVie said on Monday it would acquire Landos Biopharma in a deal worth up to $212.5 million, adding an experimental drug for ulcerative colitis to its…
NEXUS Phase 2 study of oral NX-13 (ABBV-113) in moderate-to-severe ulcerative colitis. Overall status: TERMINATED. Why stopped: 'Sponsor Decision_Not Safety…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
AbbVie acquired Landos Biopharma for $20.42/share in cash (~$137.5M upfront) plus one non-tradable CVR worth up to $11.14/share (~$75M, total up to ~$212.5M) contingent on a clinical milestone; announced March 25, 2024 and closed May 23, 2024. The deal added NX-13 (ABBV-113), a first-in-class oral NLRX1 agonist then in Phase 2 (NEXUS) for moderate-to-severe ulcerative colitis, to AbbVie's inflammatory/autoimmune pipeline behind Skyrizi and Rinvoq. UPDATE (post-close): AbbVie terminated the Phase 2 NEXUS trial (NCT05785715) — overall status TERMINATED on ClinicalTrials.gov, 'Sponsor Decision, Not Safety Related,' completion May 30, 2025 — and discontinued ABBV-113 development, citing an inadequately differentiated benefit-risk profile. With the program halted, the CVR's clinical milestone is almost certainly unattainable, leaving the realized deal value at the ~$137.5M upfront.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AbbVie Inc. / Landos Biopharma Inc. (this deal) | 2024 | $212M | — |
| AbbVie Inc. / Boehringer Ingelheim GmbH | 2016 | $2.2B | 95 |
| AbbVie Inc. / Genmab A/S | 2020 | $3.9B | 81 |
| AbbVie Inc. / Pharmacyclics Inc. | 2015 | $21.0B | 79 |
| AbbVie Inc. / Apogee Therapeutics, Inc. | 2026 | $10.9B | 72 |
| AbbVie Inc. / ImmunoGen Inc. | 2023 | $10.1B | 69 |
| AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. | 2024 | $2.0B | 64 |
← Browse all deals · How we score deals
More: 2024 deals · AbbVie Inc. deals · Gastroenterology deals